RBC Capital reiterates UnitedHealth stock rating on earnings outlook By Investing.com

RBC Capital reiterated an Outperform rating on UnitedHealth with a $361 price target and said the company is best positioned into its April 21 first-quarter earnings report. The firm’s 1Q26 adjusted EPS estimate is $6.88, about 4% above consensus, and it sees improved positioning from CMS’s better-than-expected 2027 Medicare Advantage rate update. The bullish call is tempered by ongoing RADV audit exposure and a mixed backdrop, but the stock has already rebounded 8.2% for the week.

Analysis

The setup is less about the headline rating action and more about a gradual de-risking of the UNH bear case: the market has already re-rated the stock off fear of reimbursement compression, so incremental upside now depends on whether operating slippage stops deteriorating faster than management can offset it. That makes the next two earnings prints more important than the next two months of price action — if trend stabilization shows up, the stock can keep grinding higher because positioning remains under-owned among generalists after a year-long drawdown.

The second-order beneficiary is CMS credibility, not just managed care multiples. A firmer final rate environment reduces the odds of a broader valuation reset across MA leaders, which should support peers with similar earnings sensitivity; however, UNH is uniquely levered to the market’s confidence in execution, so it should outperform the group if there is any evidence of margin repair in the care delivery / services stack. Conversely, the expanded audit regime is a real overhang because it can create a multi-quarter earnings cloud even if core utilization trends improve.

The market is likely underestimating timing risk: the stock can rally on “better than feared” commentary, but the fundamental validation point is months away, not days. That opens a classic squeeze setup into the print, but also a post-earnings fade if investors conclude that 2026 assumptions are still too optimistic or that margin recovery is pushed further out. AI-related cost-out claims are also being priced as optionality rather than an operating bridge, so they are not enough to defend the stock if medical cost trend re-accelerates.

Key Decisions for Investors

• Go long UNH into earnings with a defined-risk call spread over the next 4-6 weeks; the trade works if the market continues to pay for trend stabilization, but upside should be capped because the stock already re-rated.
• Pair long UNH / short a more operationally fragile managed care name for 1-3 months; the relative trade should express execution quality and balance sheet resilience rather than sector beta.
• If already long UNH, sell a near-dated covered call into implied volatility ahead of the April 21 catalyst; collect premium while retaining participation if the stock grinds higher on incremental confidence.
• Avoid adding aggressive size until post-print guidance on 2026 medical trend is clearer; the downside case is a multi-quarter de-rating if the company cannot prove cost discipline quickly.
• Monitor CMS/RADV headlines as the key tail risk; if audit commentary turns materially worse, reduce exposure immediately because that outcome can overwhelm any upside from reimbursement optimism.